FluiDx-AD is a collaborative project aimed at improving Alzheimer’s disease (AD) diagnosis and management through the development of innovative saliva and blood-based diagnostic tests. These tests, if validated, could improve early detection, facilitate access to next-generation treatments and enhance quality of life for the millions of people affected by AD.
On 6 February, four members of the FluiDx-AD advisory board met with Faye Forsyth and Christophe Bintener (Alzheimer Europe) for their second online meeting. The main topics of discussion were findings from a systematic review about the benefits and drawbacks of diagnosing AD via fluid-based biomarker tests. Fruitful discussions were held about the potential ethical issues and benefits, including how these vary depending on the individual context and perspective. Further, the group deliberated an ethics grounded, dynamic visualisation tool that could support people navigating the fluid-based biomarker process, potentially assisting informed decision making.
Learn more about the Public Involvement Board: https://www.fluidx-ad.eu/public-involvement/
